2 November 2020 in Journal of Clinical Investigation
BACKGROUND. Initial reports from the severe acute respiratory coronavirus 2 (SARS–CoV-2) pandemic described children as being less susceptible to coronavirus disease 2019 (COVID-19) than adults. Subsequently, a severe and novel pediatric disorder termed multisystem inflammatory syndrome in children (MIS-C) emerged. We report on unique hematologic and immunologic parameters that distinguish between COVID-19 and MIS-C and provide insight into pathophysiology. METHODS. We prospectively enrolled hospitalized patients with evidence of SARS–CoV-2 infection and classified them as having MIS-C or COVID-19. Patients with COVID-19 were classified as having either minimal or severe disease. Cytokine profiles, viral cycle thresholds (Cts), blood smears, and soluble C5b-9 values were analyzed with clinical data. RESULTS. Twenty patients were enrolled (9 severe COVID-19, 5 minimal COVID-19, and 6 MIS-C). Five cytokines (IFN-γ, IL-10, IL-6, IL-8, and TNF-α) contributed to the analysis. TNF-α and IL-10 discriminated between patients with MIS-C and severe COVID-19. The presence of burr cells on blood smears, as well as Cts, differentiated between patients with severe COVID-19 and those with MIS-C. CONCLUSION. Pediatric patients with SARS–CoV-2 are at risk for critical illness with severe COVID-19 and MIS-C. Cytokine profiling and examination of peripheral blood smears may distinguish between patients with MIS-C and those with severe COVID-19. FUNDING. Financial support for this project was provided by CHOP Frontiers Program Immune Dysregulation Team; National Institute of Allergy and Infectious Diseases; National Cancer Institute; the Leukemia and Lymphoma Society; Cookies for Kids Cancer; Alex’s Lemonade Stand Foundation for Childhood Cancer; Children’s Oncology Group; Stand UP 2 Cancer; Team Connor; the Kate Amato Foundations; Burroughs Wellcome Fund CAMS; the Clinical Immunology Society; the American Academy of Allergy, Asthma, and Immunology; and the Institute for Translational Medicine and Therapeutics.
8 March 2023 in Journal of Experimental Medicine
STAT6 (signal transducer and activator of transcription 6) is a transcription factor that plays a central role in the pathophysiology of allergic inflammation. We have identified 16 patients from 10 families spanning three continents with a profound phenotype of early-life onset allergic immune dysregulation, widespread treatment-resistant atopic dermatitis, hypereosinophilia with esosinophilic gastrointestinal disease, asthma, elevated serum IgE, IgE-mediated food allergies, and anaphylaxis. The cases were either sporadic (seven kindreds) or followed an autosomal dominant inheritance pattern (three kindreds). All patients carried monoallelic rare variants in STAT6 and functional studies established their gain-of-function (GOF) phenotype with sustained STAT6 phosphorylation, increased STAT6 target gene expression, and TH2 skewing. Precision treatment with the anti–IL-4Rα antibody, dupilumab, was highly effective improving both clinical manifestations and immunological biomarkers. This study identifies heterozygous GOF variants in STAT6 as a novel autosomal dominant allergic disorder. We anticipate that our discovery of multiple kindreds with germline STAT6 GOF variants will facilitate the recognition of more affected individuals and the full definition of this new primary atopic disorder.
17 September 2019 in Genetics in Medicine
1 September 2019 in Canadian Journal of Cardiology
22 February 2010 in Journal of Cardiovascular Electrophysiology
25 May 2026 in British Journal of Dermatology
Background: Epidermal differentiation disorders (EDDs) are inherited keratinization disorders with remarkable clinical and genetic heterogeneity. Defects in epidermal lipid metabolism and corneocyte lipid envelope assembly account for a subset of EDDs. Epoxide hydrolase 3 (EH3), encoded by EPHX3, mediates the hydrolysis of linoleate-derived lipid epoxides during barrier formation. While Ephx3-deficient mice exhibit impaired skin barrier function, no human disorders caused by EPHX3 variants have been reported to date. Objectives: To determine the genetic basis of a new subtype of nonsyndromic EDD (nEDD) presenting from early infancy with generalized erythematous patches and plaques, xerosis and skin peeling; and to assess the impact of EH3 deficiency on epidermal lipid processing. Methods: Whole-exome sequencing was performed in three unrelated families with nEDDs to investigate the underlying genetic causes. The skin biopsy from one representative patient was analysed using immunofluorescence staining and lipid staining. Liquid chromatography–mass spectrometry was used to quantify EH3 activity. Patient-derived primary keratinocytes were used to generate three-dimensional (3D) skin equivalents to assess epidermal differentiation. Results: Three affected individuals from Chinese, Pakistani Irish and Russian families with nEDDs were enrolled. Biallelic EPHX3 variants (c.74G>A, p.Trp25*; c.289G>T, p.Gly97*; c.524G>A, p.Gly175Asp; c.908G>A, p.Trp303*; c.1033delC, p.Gln345Argfs*51) were identified in the patients. Total trihydroxyoctadecenoic acid was reduced in tape-stripping stratum corneum extracts from affected individuals, suggesting reduced EH3-dependent epoxide hydrolysis in vivo. Consistently, carriers of EPHX3 variants showed markedly reduced epoxide hydrolase activity in vitro. Nile red staining of the patient’s skin lesion revealed reduced and redistributed lipids, suggesting a disturbed stratum corneum lipid barrier. The patient’s keratinocyte-constructed 3D skin equivalent showed disrupted stratum corneum, more extensive keratin 1, increased loricrin and Ki-67, and reduced claudin-1 staining. Conclusions: We report biallelic loss-of-function EPHX3 variants causing a new subtype of nEDD. Our study also supports an important role of EH3-dependent epoxide hydrolysis in epidermal barrier lipid processing.